Theravance Biopharma Sets September 18 Vote on $17/Share Zymeworks Merger
TBPH sits 30% above its 52-week low of $13.08 on light trading volume (0.3× avg).
Summary
Theravance Biopharma filed its definitive proxy statement for the $17.00 per share cash-plus-CVR acquisition by Zymeworks, setting the shareholder vote for September 18, 2026.
Key Events · M&A and Partnerships · TBPH
-
Shareholder Vote Set for September 18
The extraordinary general meeting to approve the merger will be held on September 18, 2026, with a record date of July 31, 2026. Shareholders of record as of that date are entitled to vote.
-
Merger Consideration: $17.00 Cash Plus CVR
Each ordinary share will be converted into the right to receive $17.00 in cash plus one non-tradable contingent value right (CVR) tied to future monetization of ampreloxetine.
-
Competitive Bidding Process Detailed
The proxy statement reveals a competitive process with Party A and Zymeworks, with Zymeworks ultimately increasing its offer from $16.60 to $17.00 per share and agreeing to the CVR structure.
-
Financing Secured
Zymeworks has a $350 million debt financing commitment from OMERS Life Sciences, and the merger is not subject to a financing condition.
Analysis · TBPH · Life Sciences
The definitive proxy statement finalizes the shareholder vote date for the $17.00 per share cash-plus-CVR acquisition by Zymeworks. The meeting is set for September 18, 2026, with a record date of July 31, 2026. The filing provides the full background of the competitive bidding process, the Lazard fairness opinion, and detailed financial projections. The merger is expected to close in the second half of 2026, subject to shareholder approval and other customary conditions.
At the time of this filing, TBPH was trading at $16.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $880M. The 52-week trading range was $13.08 to $21.03. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.